Bavarian Nordic Reports P-III Clinical Trial Results of CHIKV VLP (PXVX0317) for Chikungunya Virus Vaccine in Adults and Adolescents
Shots:
- The P-III trial evaluating CHIKV VLP (IM) vs PBO in 3254 patients aged 12-64yrs. CHIKV VLP met all the co-primary EPs & was shown to be highly immunogenic in the majority of patients up to 22 days post a single vaccination and demonstrated strong induction of chikungunya neutralizing Abs in 98% of vaccinees in the active group
- Induced significant neutralizing Abs in 97% of the patients at 2wks. post vaccination confirming a rapid onset of protective levels of immunity. The vaccine also showed a fast, durable response with high immunity levels at 2wks. and 6mos. post a single vaccination
- Additionally, 86% had seroprotective levels of neutralizing Abs at 6mos. post vaccination, was well-tolerated in adolescent and adult population
Ref: Globe Newswire | Image: Bavarian Nordic
Related News:- Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
